Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leonetti Alessandro, Perrone Fabiana, Puntoni Matteo, Maglietta Giuseppe, Bordi Paola, Bria Emilio, Vita Emanuele, Gelsomino Francesco, De Giglio Andrea, Gelibter Alain, Siringo Marco, Mazzoni Francesca, Caliman Enrico, Genova Carlo, Bertolini Federica, Guaitoli Giorgia, Passiglia Francesco, Delcuratolo Marco Donatello, Montrone Michele, Cerea Giulio, Pasello Giulia, Roca Elisa, Belluomini Lorenzo, Cecere Fabiana Letizia, Guida Annalisa, Manzo Anna, Adamo Vincenzo, Rastelli Francesca, Bulotta Alessandra, Citarella Fabrizio, Toschi Luca, Zoratto Federica, Cortinovis Diego Luigi, Berardi Rossana, Follador Alessandro, Carta Annamaria, Camerini Andrea, Salerno Flavio, Silva Rosa Rita, Baldini Editta, Cortellini Alessio, Brighenti Matteo, Santoni Matteo, Malorgio Francesco, Caminiti Caterina, Tiseo Marcello
Аннотация
METHODS: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs).
RESULTS: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27-85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1-17.9), median OS was 16.1 months (95% CI, 14.4-18.8) and PFS was 9.9 months (95% CI, 8.8-11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6-17.1). ORR was 43.4% (95% CI, 40.4-46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%).
CONCLUSIONS: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.